Effects and safety of iron-based phosphate binders in dialysis patients: a systematic review and meta-analysis

References

• Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379(9811):165–180
   PubMed Web of Science ®Google Scholar
• United States Renal Data System. 2013 annual data report: Atlas of end-stage renal disease. Costs of end-stage renal disease. Available at: http://www.usrds.org/2013/view/v2_11.aspx. Accessed February 12, 2014
   Google Scholar
• Bellasi A, Mandreoli M, Baldrati L, et al. Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. Clin J Am Soc Nephrol. 2011;6(4):883–891
   PubMed Web of Science ®Google Scholar
• Eddington H, Hoefield R, Sinha S, et al. Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(12):2251–2257
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70(4):771–780
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1–S201
   PubMed Web of Science ®Google Scholar
• Yamada K, Fujimoto S, Nishiura R, et al. Risk factors of the progression of abdominal aortic calcification in patients on chronic hemodialysis. Nephrol Dial Transplant. 2007;22(7):2032–2037
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes, C.K.D.M.B.D. Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1–S130
   Google Scholar
• Oka Y, Miyazaki M, Takatsu S, et al. Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage. Ther Apher Dial. 2007;11(2):107–113
   PubMedGoogle Scholar
• Dwyer JP, Sika M, Schulman G, et al. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: A short-term randomized trial. Am J Kidney Dis. 2013;61(5):759–766
   PubMed Web of Science ®Google Scholar
• Sinsakul M, Sika M, Koury M, et al. The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract. 2012;121(1–2):c25–c29
   PubMed Web of Science ®Google Scholar
• Iida A, Kemmochi Y, Kakimoto K, et al. Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification. Am J Nephrol. 2013;37(4):346–358
   PubMed Web of Science ®Google Scholar
• Block GA, Brillhart SL, Persky MS, Amer A, Slade AJ. Efficacy and safety of SBR759, a new iron-based phosphate binder. Kidney Int. 2010;77(10):897–903
   PubMed Web of Science ®Google Scholar
• Geisser P, Philipp E. PA21: A novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol. 2010;74(1):4–11
   PubMed Web of Science ®Google Scholar
• Chen JB, Chiang SS, Chen HC, et al. Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride. Nephrology (Carlton). 2011;16(8):743–750
   PubMed Web of Science ®Google Scholar
• Floege J, Covic AC, Ketteler M, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86(3):638--647
   PubMed Web of Science ®Google Scholar
• Fukagawa M, Kasuga H, Joseph D, et al. Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy. Clin Exp Nephrol. 2014;18(1):135–143
   PubMed Web of Science ®Google Scholar
• McIntyre CW, Pai P, Warwick G, Wilkie M, Toft AJ, Hutchison AJ. Iron-magnesium hydroxycarbonate (fermagate): A novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. Clin J Am Soc Nephrol. 2009;4(2):401–409
   PubMed Web of Science ®Google Scholar
• Wüthrich RP, Chonchol M, Covic A, Gaillard S, Chong E, Tumlin JA. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol. 2013;8(2):280–289
   PubMed Web of Science ®Google Scholar
• Yang WC, Yang CS, Hou CC, Wu TH, Young EW, Hsu CH. An open-label, crossover study of a new phosphate-binding agent in hemodialysis patients: Ferric citrate. Nephrol Dial Transplant. 2002;17(2):265–270
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Akiba T, Fukagawa M, et al. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transplant. 2014;29(5):1053--1060
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Hirakata H, Akiba T, Sawada K, Kumagai Y. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: Results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol. 2012;36(5):478–487
   PubMed Web of Science ®Google Scholar
• Bond C, Jensen D, Wang S, et al. A meta-analysis of ferric citrate for hyperphosphatemia: The effects of an oral iron-containing phosphate binder on serum ferritin and saturated transferrin in hemodialysis patients. Am J Nephrol. 2012;27:ii490
   Google Scholar
• Novartis Clinical Trial Results Database. A 12-week, open label, multicentre, titration study, with a 9-month maintenance treatment extension, to demonstrate efficacy of SBR759 compared to sevelamer-HCl in lowering serum phosphate levels in Chronic Kidney Disease patients on hemodialysis. Available at: http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=4664. Accessed May 25, 2014
   Google Scholar